唾液酸路易斯a | 92448-22-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 唾液酸路易斯a
• 英文名称: Sialyl Lewis a
• 英文别名: (2S,4S,5R,6R)-5-acetamido-2-[(2R,3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-2-acetamido-5,6-dihydroxy-1-oxo-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• CAS: 92448-22-1
• 化学式: C₃₁H₅₂N₂O₂₃
• 分子量: 820.7
• InChiKey: INZOTETZQBPBCE-NYLDSJSYSA-N

物化性质

• 熔点：
  >181oC (dec.)
• 沸点：
  1285.8±65.0 °C(Predicted)
• 密度：
  1.66±0.1 g/cm3(Predicted)
• 溶解度：
  甲醇（微溶）、水（微溶）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -8.6
• 重原子数：
  56
• 可旋转键数：
  18
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  411
• 氢给体数：
  15
• 氢受体数：
  23

安全信息

• WGK Germany：
  3

文献信息

• Methods to predict progression of Barrett's Esophagus to high grade dysplasia esophageal adenocarcinoma
  申请人：Medical Research Council

  公开号：US11391737B2

  公开（公告）日：2022-07-19

  In some embodiments, a method for aiding prediction of the likelihood of progression from Barrett's esophagus to high grade dysplasia or esophageal adenocarcinoma in a subject, is disclosed. The method can include (a) providing an oesophagal sample from said subject (b) determining if said sample stains abnormally with Aspergillus oryzae lectin; (c) determining if there is a DNA content abnormality in said sample; and (d) determining if there is low grade dysplasia in said sample; wherein if (b) is abnormal and (c) is abnormal and low grade dysplasia is present, then an increased likelihood of progression is determined. The disclosed subject matter also relates to an apparatus, and to different uses of certain materials.

  在一些实施方案中，公开了一种用于帮助预测受试者从巴雷特食管发展为高度发育不良或食管腺癌的可能性的方法。该方法可包括：(a) 提供来自所述受试者的食道样本；(b) 确定所述样本是否被奥氏曲霉凝集素染色异常；(c) 确定所述样本中是否存在 DNA 含量异常；以及 (d) 确定所述样本中是否存在低度发育不良；其中，如果(b)异常和(c)异常，并且存在低度发育不良，则确定恶化的可能性增加。所公开的主题还涉及一种仪器和某些材料的不同用途。
• LOW DOSE RADIATION CONDITIONING FOR IMMUNOTHERAPY
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20210236554A1

  公开（公告）日：2021-08-05

  The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable TRAIL polypeptide.
• CHIMERIC ANTIGEN RECEPTOR TARGETING SIALYL LEWIS A AND USES THEREOF
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20210246221A1

  公开（公告）日：2021-08-12

  The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., pancreatic cancer). It relates to antigen recognizing receptor (e.g., chimeric antigen receptors (CARs)) that specifically target Sialyl Lewis A (e.g., human Sialyl Lewis A), and immunoresponsive cells comprising such CARs. The presently disclosed Sialyl Lewis A-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
• [EN] CHIMERIC ANTIGEN RECEPTOR TARGETING SIALYL LEWIS A AND USES THEREOF<br/>[FR] RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES CIBLANT SIALYL LEWIS A ET LEURS UTILISATIONS
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2020081988A1

  公开（公告）日：2020-04-23

  The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., pancratic cancer). It relates to antigen recognizing receptor (e.g., chimeric antigen receptors (CARs)) that specifically target Sialyl Lewis A (e.g., human Sialyl Lewis A), and immunoresponsive cells comprising such CARs. The presently disclosed Sialyl Lewis A-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
• [EN] LOW DOSE RADIATION CONDITIONING FOR IMMUNOTHERAPY<br/>[FR] CONDITIONNEMENT DE RAYONNEMENT À FAIBLE DOSE POUR IMMUNOTHÉRAPIE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2020081979A1

  公开（公告）日：2020-04-23

  The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen¬ recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable TRAIL polypeptide.